Drug Trial Radar · NCT03733249
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
187
Actual
Start
Jan 2017
Primary completion
Jun 30, 2020
Study completion Apr 14, 2023
Sponsor
- Lead sponsor
- Bellicum PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
Conditions
- Acute Lymphoblastic Leukemia
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Primary Immunodeficiency
- Anemia, Aplastic
- Hemoglobinopathies
- Cytopenia
- Fanconi Anemia
- Diamond Blackfan Anemia
- Thalassemia
- Anemia, Sickle Cell
Interventions
RimiducidDrug
Rimiducid is administered to treat chronic graft versus host disease
rivogenlecleucelBiological
donor T-cells modified with iCasp safety switch
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 1 and 2 years after rivogenlecleucel infusion
- Incidence of Disease-free SurvivalTime frame: 1 and 2 years after rivogenlecleucel infusion
- Relapse-free SurvivalTime frame: 1 and 2 years after rivogenlecleucel infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.